Verónica Miguela

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Our study represents the most extensive preclinical characterisation of palbociclib for HCC treatment to date and supports its clinical development, alone or in combination with sorafenib. Further studies will optimise patient target selection as well as the best treatment combinations. Here, we provide a comprehensive preclinical evaluation of palbociclib activity in HCC. Treatment with palbociclib induced a reversible cell cycle arrest that depended on an intact RB1.

Objective Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive breast cancer. RB1 is rarely mutated in HCC, suggesting that palbociclib could potentially be used for HCC therapy. Here, we provide a comprehensive characterisation of the efficacy of palbociclib in multiple preclinical models of HCC.